Insmed CEO to Present at Drug Discovery & Development Conference
Dr. Allan will be participating in the Orphan Diseases track of theconference and his presentation will be entitled, "Myotonic Muscular Dystrophy- A Major Unmet Medical Need." He will present Insmed's progress with itsPhase II trial for IPLEX(TM) in Myotonic Muscular Dystrophy. The trial, whichhas seen strong patient and physician interest, is now fully enrolled. It is asix month, randomized, double-blind, placebo-controlled trial being conductedat 13 research centers across the U.S.
The conference will be held from August 4th to August 7th, 2008, at theWorld Trade Center Boston and the Seaport Hotel in Boston, MA.
Insmed Inc. is a biopharmaceutical company with unique protein processdevelopment and manufacturing experience and a proprietary protein platformaimed at niche markets with unmet medical needs. For more information, pleasevisit www.insmed.com.
This release contains forward-looking statements which are made pursuantto provisions of Section 21E of the Securities Exchange Act of 1934. Investorsare cautioned that such statements in this release, including statementsrelating to planned clinical study design, regulatory and business strategies,strategic alternatives, plans and objectives of management and growthopportunities for existing or proposed products, constitute forward-lookingstatements which involve risks and uncertainties that could cause actualresults to differ materially from those anticipated by the forward-lookingstatements. The risks and uncertainties include, without limitation, risksthat strategic alternatives may never be consummated, product candidates mayfail in the clinic or may not be successfully marketed or manufactured, we maylack financial resources to complete development of product candidates, theFDA may interpret the results of studies differently than us, competingproducts may be more successful, demand for new pharmaceutical products maydecrease, the biopharmaceutical industry may experience negative markettrends, our entrance into the follow-on biologics market may be unsuccessful,our common stock could be delisted from The NASDAQ Capital Market and otherrisks and challenges detailed in the Company's filings with the U.S.Securities and Exchange Commission, including the Company's Annual Report onForm 10-K for the year ended December 31, 2007. Readers are cautioned not toplace undue reliance on any forward-looking statements which speak only as ofthe date of this release. The Company undertakes no obligation to publiclyrelease the results of any revisions to these forward-looking statements thatmay be made to reflect events or circumstances that occur after the date ofthis release or to reflect the occurrence of unanticipated events.Investor Relations Contact: Brian Ritchie - FD 212-850-5683 email@example.com Corporate Communications Contact: John Procter - Gibraltar Associates 202-879-5808 firstname.lastname@example.org
SOURCE Insmed Inc.
You May Also Like